Are We Doing Better with Large-Bowel Cancer?

Publisher Website
Google Scholar
Abstract
AS the second leading cause of death from neoplasia, large-bowel cancer commands the attention of many kinds of physicians. Although the treatment of large-bowel cancer has historically been, and still is, surgical, today gastroenterologists, radiation therapists, medical oncologists, immunologists, family physicians, and pathologists are also committed to preventing, treating, and learning about this disease. In this issue of the Journal, the Gastrointestinal Tumor Study Group (GITSG)1 reports the results of a careful randomized study of patients with colon cancer. They found no benefit when patients were treated with adjuvant chemotherapy with fluorouracil and semustine, nonspecific immunotherapy with the methanol . . .